Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. Abstract Text:

Soocheol Jeong,Hiroshi Aikata,Yoshio Katamura,Takahiro Azakami,Tomokazu Kawaoka,Hiromi Saneto,Kiminori Uka,Nami Mori,Shintaro Takaki,Hideaki Kodama,Koji Waki,Michio Imamura,Hiroo Shirakawa,Yoshiiku Kawakami,Shoichi Takahashi,Kazuaki Chayama,

AIM: To assess the efficacy of low-dose intermittent interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related compensated cirrhosis who had received curative treatment for primary hepatocellular carcinoma (HCC). METHODS: We performed a prospective case controlled study. Sixteen patients received 3 MIU of natural IFN-alpha intramuscularly 3 times weekly for at least 48 wk (IFN group). They were compared with 16 matched historical controls (non-IFN group). RESULTS: The cumulative rate of first recurrence of HCC was not significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 68.6% vs 80% at 1- and 3-year, P = 0.157, respectively). The cumulative rate of second recurrence was not also significantly different between the IFN group and the non-IFN group (0% vs 6.7% and 35.9% vs 67% at 1- and 3-year, P = 0.056, respectively). Although the difference in the Child-Pugh classification score between the groups at initial treatment of HCC was not significant, the score was significantly worse at the time of data analysis in the non-IFN group than IFN group (7.19 +/- 1.42 vs 5.81 +/- 0.75, P = 0.0008). The cumulative rate of deviation from objects of any treatment for recurrent HCC was also higher in the non-IFN group than IFN group (6.7% and 27% vs 0 and 0% at 1- and 3-year, P = 0.048, respectively). CONCLUSION: Low-dose intermittent IFN-alpha therapy for patients with HCV-related compensated cirrhosis after curative HCC treatment was effective by making patients tolerant to medical or surgical treatment for recurrent HCC in the later period of observation.

Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. Publishing Authors By Initials

S Jeong,H Aikata,Y Katamura,T Azakami,T Kawaoka,H Saneto,K Uka,N Mori,S Takaki,H Kodama,K Waki,M Imamura,H Shirakawa,Y Kawakami,S Takahashi,K Chayama,

For similar investigative techniques: epidemiologic methods: epidemiologic study characteristics as topic: epidemiologic studies: cohort studies: longitudinal studies: prospective studies research abstracts see: investigative techniques: epidemiologic methods: epidemiologic study characteristics as topic: epidemiologic studies: cohort studies: longitudinal studies: prospective studies research

PUBMED ID PMID:

MEDLINE DATE:

Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: World journal of gastroenterology : WJG

VOLUME: 13

Page Numbers: 5188-95

Journal Abbreviation: World J. Gastroenterol.

ISSN: 1007-9327

DAY: 21

MONTH: Oct

YEAR: 2007

Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100883448

Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. Keywords Mesh Terms:

KEYWORDS: Prospective Studies

MESH TERMS: prevention & control

Chemical & Substance for Abstract: Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. Information

Substance Name: Interferon-alpha

Registry Number: 0

Grant and Affiliation Information for Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

AFFILIATION: Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Hiroshima, Japan.

Country: China

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: World J Gastroenterol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma Related Publications

• A case of multiple hepatic peribiliary cysts which contributed to the obstructive jaundice and led to liver failure at the young man with von Recklinghausen's disease.
• A case report of anaphylactoid purpura with acute abdominal pain secondary to trauma caused by traffic accident.
• Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.
• Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemorrhage.
• Clinical significance of type V(I) pit pattern subclassification in determining the depth of invasion of colorectal neoplasms.
• Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
• Efficacy of percutaneous cementoplasty for bone metastasis from hepatocellular carcinoma.
• Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-alpha and Ribavirin. A Prospective Randomized Controlled Trial.
• Evaluation of Gastric Cancer Risk Using Topography of Histological Gastritis: A Large-scaled Cross-sectional Study.
• Evaluation of colon cancer vascularity by flash echo imaging.
• Evaluation of microvessels in colorectal tumors by narrow band imaging magnification.
• Genetic polymorphisms and head and neck cancer risk (Review).
• Helicobacter pylori-associated gastritis is related to babA2 expression without heterogeneity of the 3' region of the cagA genotype in gastric biopsy specimens.
• Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer.
• Long-term Ultrasonographic Follow-up Study of Gastric Motility in Patients with Functional Dyspepsia.
• Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.
• Predicting the need for surgery in Crohn's disease with contrast harmonic ultrasound.
• Predictors and long-term prognostic implications of angiographic slow/no-flow during percutaneous coronary intervention for acute myocardial infarction.
• Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
• Primary follicular lymphoma of the gastrointestinal tract: a retrospective case series.
• Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy.
• Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study.
• Role of Helicobacter pylori infection and chronic inflammation in gastric cancer in the cardia.
• Selective decrease in colonic CD56(+) T and CD161(+) T cells in the inflamed mucosa of patients with ulcerative colitis.
• Serum pepsinogen levels in the Japanese population: prospective study of 9 years of follow-up.
• Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
• Strategy for treatment of nonerosive reflux disease in Asia.
• Successful treatment of an entecavir-resistant hepatitis B virus variant.
• Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases.
• The number of criminal prosecutions against physicians due to medical negligence is on the rise in Japan.